Opinion, Henning Mann, PhD, HM.BioConsulting Download the full article as PDF INTRODUCTION Emerging and growth-stage companies are still operating under real financial discipline, and runways are being managed in quarters. Investors and boards are scrutinizing burn rate as closely as pipeline progress, and every senior hire now carries an opportunity cost measured against the next R&D milestone. Almost every company in this position genuinely needs commercial or business de